Literature DB >> 2142722

Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.

M R Alderson1, H M Sassenfeld, M B Widmer.   

Abstract

The effects of purified recombinant interleukin 7 (IL-7) on the generation of cytolytic T lymphocytes (CTL) in mixed lymphocyte culture (MLC) and on the induction of lymphokine-activated killer (LAK) cells in autologous cultures of human peripheral blood mononuclear cells were investigated. IL-7 was found to induce the generation of both CTL and LAK cells in bulk cultures. The appearance of peak CTL activity in MLC established with exogenous IL-7 was delayed in comparison with replicate cultures containing exogenous IL-2, but both cytokines stimulated quantitatively similar levels of antigen-specific lytic activity. An IL-2-neutralizing antiserum inhibited substantially, but not completely, the effect of IL-7 on CTL generation, implying the existence of both an indirect component of IL-7 activity via IL-2 utilization, as well as an IL-2-independent component. Cell surface phenotypic analysis of IL-2- or IL-7-generated CTL effector cells revealed that CD8+ cells were responsible for the vast majority of lytic activity. Limiting dilution analysis (LDA) revealed that essentially identical frequencies of CTL precursors (CTL-P) were capable of clonal expansion and/or differentiation in the presence of exogenous IL-2, IL-4, or IL-7, supporting the concept that all three of these cytokines are capable of exerting a major influence on T cell growth and differentiation. Approximately half of the CTL-P that responded in IL-7-supplemented LDA cultures did so in an IL-2-independent manner. IL-7 stimulated the development of LAK cells in autologous bulk cultures, but only weakly in comparison with IL-2. In contrast to its effects on CTL generation, the induction of LAK cells by IL-7 was virtually independent of IL-2. LAK cells induced by IL-7, like those induced by IL-2, were phenotypically heterogeneous and included CD8+, CD56+, and gamma/delta+ cells. Limiting dilution analysis indicated that IL-2 stimulated fivefold more LAK-P than IL-7 and 220-fold more than IL-4. Collectively, these data suggest that IL-7 has potent regulatory effects on human cytolytic cell populations and, either alone or in combination with other cytokines, could be important for the in vitro expansion of cells for adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142722      PMCID: PMC2188337          DOI: 10.1084/jem.172.2.577

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  Regulation of T cell proliferation by IL-7.

Authors:  K H Grabstein; A E Namen; K Shanebeck; R F Voice; S G Reed; M B Widmer
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

2.  A T-cell receptor gamma/CD3 complex found on cloned functional lymphocytes.

Authors:  J Borst; R J van de Griend; J W van Oostveen; S L Ang; C J Melief; J G Seidman; R L Bolhuis
Journal:  Nature       Date:  1987 Feb 19-25       Impact factor: 49.962

3.  T cell nature of some lymphokine-activated killer (LAK) cells. Frequency analysis of LAK precursors within human T cell populations and clonal analysis of LAK effector cells.

Authors:  L Moretta; D Pende; R Cozzani; A Merli; M Bagnasco; M C Mingari
Journal:  Eur J Immunol       Date:  1986-12       Impact factor: 5.532

4.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

5.  Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway.

Authors:  S C Meuer; R E Hussey; D A Cantrell; J C Hodgdon; S F Schlossman; K A Smith; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

6.  Lymphokine purification by reversed-phase high-performance liquid chromatography.

Authors:  D L Urdal; D Mochizuki; P J Conlon; C J March; M L Remerowski; J Eisenman; C Ramthun; S Gillis
Journal:  J Chromatogr       Date:  1984-07-27

7.  Lymphokine-activated killer cells. Analysis of progenitors and effectors.

Authors:  J R Ortaldo; A Mason; R Overton
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

8.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

Authors:  J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

9.  B cell stimulatory factor 1 (interleukin 4) is a potent costimulant for normal resting T lymphocytes.

Authors:  J Hu-Li; E M Shevach; J Mizuguchi; J Ohara; T Mosmann; W E Paul
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  33 in total

1.  The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma.

Authors:  G G Steger; M F Gnant; M P Djavanmard; R M Mader; R Jakesz; W Pierce; J B deKernion; R Figlin; A Belldegrun
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  The serum factor from patients with ulcerative colitis that induces T cell proliferation in the mouse thymus is interleukin-7.

Authors:  M Watanabe; N Watanabe; Y Iwao; H Ogata; T Kanai; Y Ueno; M Tsuchiya; H Ishii; S Aiso; S Habu; T Hibi
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

3.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.

Authors:  T Aoki; K Tashiro; S Miyatake; T Kinashi; T Nakano; Y Oda; H Kikuchi; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

Review 4.  The immunology of parasite infections in immunocompromised hosts.

Authors:  T Evering; L M Weiss
Journal:  Parasite Immunol       Date:  2006-11       Impact factor: 2.280

5.  IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).

Authors:  G Ferrari; K King; K Rathbun; C A Place; M V Packard; J A Bartlett; D P Bolognesi; K J Weinhold
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

6.  Stimulation of B-cell lymphopoiesis by interleukin-7 leads to aggravation of murine leishmaniasis.

Authors:  A Gessner; A Will; M Vieth; K Schröppel; M Röllinghoff
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

7.  Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.

Authors:  W J Murphy; T C Back; K C Conlon; K L Komschlies; J R Ortaldo; T J Sayers; R H Wiltrout; D L Longo
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

8.  Combined activation of murine lymphocytes with staphylococcal enterotoxin and interleukin-2 results in additive cytotoxic activity.

Authors:  H Belfrage; P Bhiladvala; G Hedlund; M Dohlsten; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

9.  Characterization of histamine-releasing activity: role of cytokines and IgE heterogeneity.

Authors:  T N Liao; K H Hsieh
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

10.  Interleukin-7 is a growth factor for Sézary lymphoma cells.

Authors:  A Dalloul; L Laroche; M Bagot; M D Mossalayi; C Fourcade; D J Thacker; D E Hogge; H Merle-Béral; P Debré; C Schmitt
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.